Genprex, Inc.

115 articles with Genprex, Inc.

• Genprex to Present at Upcoming Investor Conference in May 2022

  5/19/2022

  Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes.

• Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

  5/9/2022

  Genprex, Inc. today announced that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert panelist at the 33rd Annual Cancer Progress Conference, taking place virtually May 10-12, 2022.

• Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

  5/5/2022

  Genprex, Inc. announced that it has issued a shareholder letter and corporate update outlining the Company's recent progress in its clinical development programs and key milestones and achievements for 2022 and beyond.

• Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022

  4/18/2022

  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that its executive leaders will be providing an overview of the Company's gene therapies for cancer and diabetes to investors and industry professionals at the following investor and industry conferences in April 2022.

• Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

  3/31/2022

  Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer.

• Genprex to Participate in Upcoming Investor Conference in March 2022

  3/23/2022

  Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO Europe Spring Investor Conference.

• 

  Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR's Next Step

  3/7/2022

  The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.

• Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

  3/2/2022

  Genprex, Inc. today announced that the first patient was dosed in the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy,

• Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

  2/9/2022

  Genprex, Inc. announced that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO CEO and Investor Conference and at the 2022 Diamond Equity Research Conference.

• Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

  1/27/2022

  Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), today announced that its collaborators published positive preclinical data for the use of Genprex’s ONCOPREX® Nanoparticle Delivery System for delivery of a FAS DNA plasmid to treat metastatic colorectal cancer.

• Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

  1/10/2022

  Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), today announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial which combines the Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid) Immunogene Therapy with AstraZeneca’s Tagrisso®, as a potential innovative treatment for non-small cell lung cancer (NSCLC).

• Genprex to Participate in January 2022 Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

  1/5/2022

  Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced its participation in upcoming investor and healthcare conferences to be held in January 2022.

• Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

  1/4/2022

  Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has expanded its oncology research and development pipeline to include small cell lung cancer (SCLC) as an additional disease indication for its lead drug candidate, REQORSA™ Immunogene Therapy.

• Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

  1/3/2022

  Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda®

• Genprex to Present in November CEO Roadshow Webinar

  11/16/2021

  Genprex, Inc. today announced that its President and Chief Executive Officer, Rodney Varner, will be presenting in November

• Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

  9/28/2021

  Genprex, Inc. announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.

• Genprex to Participate in a Monthly CEO Roadshow Webinar Series

  7/20/2021

  Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

• Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

  6/23/2021

  Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso ® to Treat Non-Small Cell Lung Cancer Following FDA Review

• Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

  5/19/2021

  Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

• Genprex to Participate in Upcoming May Investor Conferences

  5/10/2021

  Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will participate in the following investor conferences in the month of May